Observational studyBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Registry-linked trialAbstract readObservational Study
In one paragraph
Observational study in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06756061 (A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease), which is not on this map. Cited by 220 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed, 7 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease
Who cites it
220 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.The Cochrane database of systematic reviews · 2023Pooled it
- Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force.Transplantation and cellular therapy · 2022Guideline
- Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review.Stem cell research & therapy · 2022Pooled it
- Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.Stem cell research & therapy · 2020Pooled it
- The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.International journal of molecular sciences · 2019Pooled it
- Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis.Bone marrow transplantation · 2019Pooled it
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.Clinical pharmacology and therapeutics · 2025Trial
- Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.Blood advances · 2025Trial
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study.Clinical drug investigation · 2025Trial
- Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation.Blood advances · 2025Trial
- A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.Blood advances · 2022Trial
- A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.Blood advances · 2022Trial
- Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease.British journal of haematology · 2021Trial
- Trial
- Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2019Trial
160 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors.
Sally AraiDivision of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California.
Mukta AroraDivision of Hematology, Oncology and Transplant, University of Minnesota Medical Center, Minneapolis, Minnesota.
Tao WangCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
Stephen R SpellmanCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.
Wensheng HeCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Daniel R CourielDivision of Hematology/Oncology, The University of Michigan, Ann Arbor, Michigan.
Alvaro Urbano-IspizuaDivision of Hematology/Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
Corey S CutlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Andrea A BacigalupoDepartment of Hematology, IRCCS AOU San Martino-IST, Genoa, Italy.
Minoo BattiwallaBranch of Hematology, National Heart Lung and Blood Institute, Bethesda, Maryland.
Mary E FlowersFred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
Mark B JuckettDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Stephanie J LeeDivison of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alison W LorenDivision of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
Thomas R KlumppDivison of Bone Marrow Transplantation, Temple Bone Marrow Transplant Program, Philadelphia, Pennsylvania.
Susan E ProckupDivison of Bone Marrow Transplant, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Olle T H RingdénDivision of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Gérard SociéDivision of Hematology, Hôpital Saint Louis, Paris, France.
Kirk R SchultzDepartment of Pediatric Hematology/Oncology/BMT, British Columbia's Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Thomas SpitzerDepartment of Bone Marrow Transplant-Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Takanori TeshimaKyushu University Hospital, Fukuoka, Japan.
Christopher N BredesonDepartment of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
David A JacobsohnDivision of Blood and Marrow Transplantation Center for Cancer and Blood Disorders, Children's National Health Systems, Washington, DC.
Robert J HayashiDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
William R DrobyskiDepartment of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Haydar A FrangoulDivision of Hematology-Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Görgün AkpekSection of Hematology Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.
Vincent T HoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Victor A LewisDepartments of Oncology, Paediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
Robert Peter GaleDivision of Experimental Medicine, Department of Medicine, Hematology Research Centre, Imperial College London, London, United Kingdom.
John KorethDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nelson J ChaoDivision of Cell Therapy and Hematologica, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Mahmoud D AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Brenda W CooperDepartment of Medicine-Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, Ohio.
Mary J LaughlinMedical Director, Cleveland Cord Blood Center, Cleveland, Ohio.
Jack W HsuDivision of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, Florida.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Leo F VerdonckDepartment of Internal Medicine, Isala Clinics, Zwolle, Netherlands.
Melhelm M SolhFlorida Center for Cellular Therapy, Florida Hospital, Orlando, Florida.
Maxim NorkinDivision of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, Florida.
Vijay ReddyDivision of Hematology/Oncology, University of Florida, Gainesville, Florida.
Rodrigo MartinoDepartment of Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Shahinaz GadallaDivision of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland.
Jenna D GoldbergBone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip L McCarthyBlood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
José A Pérez-SimónDepartment of Hematology, Instituto de Biomedicina de Sevilla, Seville, Spain.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
Ian D LewisHaematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan.
Richard F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden.
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Edmund K WallerWinship Cancer Institute, Emory University, Atlanta, Georgia.
Didier BlaiseDeparment of Hematology, Institut Paoli Calmettes, Marseille, France.
Joseph A PidalaH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Paul J MartinDivison of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Prakash SatwaniDivision of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, New York.
Martin BornhäuserDepartment of Internal Medicine, University Hospital Dresden, Dresden, Germany.
Yoshihiro InamotoDivison of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Daniel J WeisdorfDivision of Hematology, Oncology and Transplant, University of Minnesota Medical Center, Minneapolis, Minnesota.
Mary M HorowitzCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Steven Z PavleticNIH-NCI Experimental Transplantation and Immunology Branch, Bethesda, Maryland. Electronic address: pavletis@mail.nih.gov.
Graft-vs-Host Disease Working Committee of the CIBMTR
Funding
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MPB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3MGenetic Epidemiology of Telomere Maintenance and Cancer EtiologyZIACP010190 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$10.2MIntegrative Molecular Epidemiology WorkshopR25CA174664 · NCI · AMERICAN ASSOCIATION FOR CANCER RESEARCH · PI Shelley S Tworoger · 2013 to 2026
$2.8MNCI NIH HHS P30 CA016056NCI NIH HHS R25 CA174664NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA76518NHLBI NIH HHS 5U01HL069294NHLBI NIH HHS U01 HL069294
Abstract
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.
Indexed as
AdolescentAdultBone Marrow TransplantationChildChild, PreschoolChronic DiseaseFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInfantInfant, NewbornInternational CooperationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMyeloablative AgonistsAllogeneic transplantcGVHDIncidenceNonrelapse mortality
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06756061ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.